Sandoz delivers 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to UN and joins UN Pneumonia Innovations Team
Pneumonia is the leading cause of infectious death globally among children under five, killing 1 million children each year and amoxicillin is the #1 treatment for childhood pneumonia
Holzkirchen, October 23, 2014 – Sandoz today announces the delivery of 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to the United Nations (UN). This follows Sandoz’ commitment to the UN Every Newborn Action Plan, launched in June 2014, which involves a long-term agreement to helping to prevent the deaths of millions of children worldwide by supplying this key antibiotic formulation.
“We are delighted to announce this first delivery on our promise to support the UN in this important global health mission,” said Nick Haggar, Head of Western Europe, Middle East and Africa for Sandoz. “We are proud to be playing a leading role in the response to the growing global need for this new formulation of anti-infective, recommended by the World Health Organization as the first-line treatment for pneumonia in children under five.”
The long-term global supplies of amoxicillin 250mg DT will reach developing countries through the UN Commission for Lifesaving Commodities for Women and Children.
Also following the commitment to UN Action Plan, Sandoz is now an active member of the UN Pneumonia Innovations Team, a global network of more than 140 organizations committed to reducing child deaths from pneumonia.
There are an estimated 155 million cases of childhood pneumonia each year and the vast majority does not receive the recommended amoxicillin dispersible tablet. One million children die each year from pneumonia. The UN launched the Every Newborn Action Plan in June 2014, the world’s first comprehensive plan to eliminate preventable deaths of newborn and stillborn babies.
Amoxicillin is a penicillin-class, broad-spectrum antibiotic, commonly prescribed to children for treatment of pneumonia and other illnesses including bacterial infections of the ears, sinuses, throat, urinary tract, skin, abdomen and blood; it is also often used as part of the treatment regime for Severe Acute Malnutrition (SAM).
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).